Label-free array system market to be worth $1,600 million by 2025, study finds
Posted: 14 April 2020 | Victoria Rees (Drug Target Review) | No comments yet
The global label-free array system market will grow at a compound annual growth rate of 7.44 percent in the forecast period, says new research.
New research has found that the global label-free array system market is set to grow at a compound annual growth rate (CAGR) of 7.44 percent in the forecast period 2018 to 2025. This imaging technique is used by academic and research institutes, contract research organisations (CROs) and pharmaceuticals and biotechnology industries, says the report.
Conducted by Reportlinker, the findings suggest that the value of the array system market will increase from $980.12 million to $1,620.12 million by the end of the forecast period.
According to the research, label-free array systems can be used across biomolecular interaction studies, detection of disease biomarkers and drug discovery.
Drug Target Review has just announced the launch of its NEW and EXCLUSIVE report examining the evolution of AI and informatics in drug discovery and development.
In this 63 page in-depth report, experts and researchers explore the key benefits of AI and informatics processes, reveal where the challenges lie for the implementation of AI and how they see the use of these technologies streamlining workflows in the future.
Also featured are exclusive interviews with leading scientists from AstraZeneca, Auransa, PolarisQB and Chalmers University of Technology.
The report highlights that the leaders in the label-free array market include Agilent Technologies, Bio-Rad Laboratories, GE Healthcare and PerkinElmer.
The market is also split into several sections including:
- Atomic force microscopy
- Ellipsometry techniques
- Enthalpy array
- Microcantilever
- Scanning kelvin nanoprobe
- Surface plasmon resonance.
Related topics
Analytical techniques, Disease research, Imaging, Label-free
Related organisations
Agilent Technologies, Bio-Rad Laboratories, GE Healthcare, PerkinElmer
